Phase Ib Study of the MEK Inhibitor Cobimetinib (GDC-0973) in Combination with the PI3K Inhibitor Pictilisib (GDC-0941) in Patients with Advanced Solid Tumors

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2019 Apr 26

PMID 31020608

Citations 46

Authors

Geoffrey I Shapiro

Patricia LoRusso

Eunice Kwak

Susan Pandya

Charles M Rudin

Carla Kurkjian

James M Cleary

Mary Jo Pilat

Suzanne Jones

Alex De Crespigny

Jill Fredrickson

Luna Musib

Yibing Yan

Matthew Wongchenko

Hsin-Ju Hsieh

Mary R Gates

Iris T Chan

Johanna Bendell

Affiliations

Soon will be listed here.

Abstract

Purpose We investigated the combination of the MEK inhibitor, cobimetinib, and the pan-PI3K inhibitor, pictilisib, in an open-label, phase Ib study. Experimental Design Patients with advanced solid tumors were enrolled in 3 dose escalation schedules: (1) both agents once-daily for 21-days-on 7-days-off ("21/7"); (2) intermittent cobimetinib and 21/7 pictilisib ("intermittent"); or (3) both agents once-daily for 7-days-on 7-days-off ("7/7"). Starting doses for the 21/7, intermittent, and 7/7 schedules were 20/80, 100/130, and 40/130 mg of cobimetinib/pictilisib, respectively. Nine indication-specific expansion cohorts interrogated the recommended phase II dose and schedule. Results Of 178 enrollees (dose escalation: n = 98), 177 patients were dosed. The maximum tolerated doses for cobimetinib/pictilisib (mg) were 40/100, 125/180, and not reached, for the 21/7, intermittent, and 7/7 schedules, respectively. Six dose-limiting toxicities included grade 3 (G3) elevated lipase, G4 elevated creatine phosphokinase, and G3 events including fatigue concurrent with a serious adverse event (SAE) of diarrhea, decreased appetite, and SAEs of hypersensitivity and dehydration. Common drug-related adverse events included nausea, fatigue, vomiting, decreased appetite, dysgeusia, rash, and stomatitis. Pharmacokinetic parameters of the drugs used in combination were unaltered compared to monotherapy exposures. Confirmed partial responses were observed in patients with BRAF-mutant melanoma (n = 1) and KRAS-mutant endometrioid adenocarcinoma (n = 1). Eighteen patients remained on study ≥6 months. Biomarker data established successful blockade of MAP kinase (MAPK) and PI3K pathways. The metabolic response rate documented by FDG-PET was similar to that observed with cobimetinib monotherapy. Conclusions Cobimetinib and pictilisib combination therapy in patients with solid tumors had limited tolerability and efficacy.

Citing Articles

EPLIN, a prospective oncogenic molecule with contribution to growth, migration and drug resistance in pancreatic cancer.

Zeng J, Wang C, Ruge F, Ji E, Martin T, Sanders A Sci Rep. 2024; 14(1):30850.

PMID: 39730634 PMC: 11680852. DOI: 10.1038/s41598-024-81485-w.

Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in -mutated colorectal cancer.

Ghosh S, Fan F, Powell R, Park Y, Stephan C, Kopetz E Ther Adv Med Oncol. 2024; 16:17588359241303302.

PMID: 39664300 PMC: 11632859. DOI: 10.1177/17588359241303302.

Regulation of PI3K signaling in cancer metabolism and PI3K-targeting therapy.

Han B, Lin X, Hu H Transl Breast Cancer Res. 2024; 5:33.

PMID: 39534586 PMC: 11557167. DOI: 10.21037/tbcr-24-29.

The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export.

Tripathi B, Hirsh N, Qian X, Durkin M, Wang D, Papageorge A Nat Cancer. 2024; 5(12):1902-1918.

PMID: 39528835 PMC: 11663792. DOI: 10.1038/s43018-024-00847-5.

Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?.

Ouissam A, Hind C, Sami Aziz B, Said A Ther Adv Med Oncol. 2024; 16:17588359241284911.

PMID: 39399412 PMC: 11468005. DOI: 10.1177/17588359241284911.

References

Deng Y, Musib L, Choo E, Chapple M, Burke S, Johnson J . Determination of cobimetinib in human plasma using protein precipitation extraction and high-performance liquid chromatography coupled to mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2014; 972:117-23. DOI: 10.1016/j.jchromb.2014.09.034. View

Turke A, Song Y, Costa C, Cook R, Arteaga C, Asara J . MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 2012; 72(13):3228-37. PMC: 3515079. DOI: 10.1158/0008-5472.CAN-11-3747. View

Hoeflich K, Merchant M, Orr C, Chan J, Otter D, Berry L . Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res. 2011; 72(1):210-9. DOI: 10.1158/0008-5472.CAN-11-1515. View

Salphati L, Wong H, Belvin M, Bradford D, Edgar K, Prior W . Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos. 2010; 38(9):1436-42. DOI: 10.1124/dmd.110.032912. View

Hatzivassiliou G, Haling J, Chen H, Song K, Price S, Heald R . Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature. 2013; 501(7466):232-6. DOI: 10.1038/nature12441. View

Tolcher A, Peng W, Calvo E . Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors. Mol Cancer Ther. 2018; 17(1):3-16. DOI: 10.1158/1535-7163.MCT-17-0349. View

Bedard P, Tabernero J, Janku F, Wainberg Z, Paz-Ares L, Vansteenkiste J . A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res. 2014; 21(4):730-8. DOI: 10.1158/1078-0432.CCR-14-1814. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

Grilley-Olson J, Bedard P, Fasolo A, Cornfeld M, Cartee L, Razak A . A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors. Invest New Drugs. 2016; 34(6):740-749. PMC: 7574157. DOI: 10.1007/s10637-016-0377-0. View

10.

Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma A . Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 2000; 35(13):1773-82. DOI: 10.1016/s0959-8049(99)00229-4. View

11.

Aoki M, Batista O, Bellacosa A, Tsichlis P, Vogt P . The akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci U S A. 1998; 95(25):14950-5. PMC: 24556. DOI: 10.1073/pnas.95.25.14950. View

12.

Wong H, Vernillet L, Peterson A, Ware J, Lee L, Martini J . Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res. 2012; 18(11):3090-9. DOI: 10.1158/1078-0432.CCR-12-0445. View

13.

McCubrey J, Steelman L, Kempf C, Chappell W, Abrams S, Stivala F . Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol. 2011; 226(11):2762-81. DOI: 10.1002/jcp.22647. View

14.

Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S . PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 275(5308):1943-7. DOI: 10.1126/science.275.5308.1943. View

15.

Wainberg Z, Alsina M, Soares H, Brana I, Britten C, Del Conte G . A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Target Oncol. 2017; 12(6):775-785. PMC: 5700209. DOI: 10.1007/s11523-017-0530-5. View

16.

Sarker D, Ang J, Baird R, Kristeleit R, Shah K, Moreno V . First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2014; 21(1):77-86. PMC: 4287394. DOI: 10.1158/1078-0432.CCR-14-0947. View

17.

Shimizu T, Tolcher A, Papadopoulos K, Beeram M, Rasco D, Smith L . The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res. 2012; 18(8):2316-25. DOI: 10.1158/1078-0432.CCR-11-2381. View

18.

Spoerke J, OBrien C, Huw L, Koeppen H, Fridlyand J, Brachmann R . Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res. 2012; 18(24):6771-83. DOI: 10.1158/1078-0432.CCR-12-2347. View

19.

Jokinen E, Koivunen J . MEK and PI3K inhibition in solid tumors: rationale and evidence to date. Ther Adv Med Oncol. 2015; 7(3):170-80. PMC: 4406912. DOI: 10.1177/1758834015571111. View

20.

Sos M, Fischer S, Ullrich R, Peifer M, Heuckmann J, Koker M . Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A. 2009; 106(43):18351-6. PMC: 2757399. DOI: 10.1073/pnas.0907325106. View